Revive Therapeutics is the leading company in producing cannabis-based pharmaceuticals in order to treat and prevent many diseases. The company is founded on the research that marijuana is an excellent healer of many illnesses mentioned below. They are, in fact, a specialty cannabis company that predominantly focuses on the development as well as commercialization of products that contain cannabinoids, or the substances found in cannabis such as THC and CBD that have been proven as the most active and most effective in treating any health problems.
Revive Therapeutics: Highest-quality Cannabis Products
The reason why this Toronto-based company is featured is that they not only focus on producing and selling marijuana-based products, but Revive Therapeutics also devotes time, energy, and money into the research of new and improved cannabinoid-based products. Because without progress we will be stuck not getting the wanted results from the cannabis medical treatments.
Revive Therapeutics is currently introducing new and improved cannabis-based products that are ready for commercialization. So far, these will be best-in-class giving the company a first-mover advantage in the so far multi-billion marijuana market, as well as in the wellness market overall.
Revive Therapeutics’ first products
Laboratory scientist via Pixabay.
Revive Therapeutics’ have commercialized their first product which is a chewing gum, RELICANN™. This medicinal product is a hemp-based Cannabidiol (containing CBD) that is actively used for the health and wellness of patients. As part of the medical cannabis market, Revive Therapeutics’ chewing gum offers an improved alternative over the currently used conventional products that did not deliver the wanted results in patients suffering from certain illnesses. Namely, the Revive Therapeutics’ RELICANN™ is specially developed and advanced to the point to fill the so-far unmet needs of the medical market that lacks effective treatments against inflammation, numerous diseases, wound care, disorders, and chronic pain.
Furthermore, Revive Therapeutics’ cannabis-based portfolio mostly focuses on liver diseases that are rare and so far there had not been an effective treatment discovered for them. For instance, the FDA has granted an orphan drug to Revive Therapeutics that is based on CBD solely and is designed for the treatment of the autoimmune disease called hepatitis. This drug is further into examination before it gets introduced to the market of marijuana products.
Top-notch Strategies of Revive Therapeutics
The unique marijuana-based products that are focused on treating rare diseases have a strategy to improve the entire medicinal marijuana product production. As the company’s president states, their products will create a base for lower development costs, while increasing the speed with which a certain product in commercialized and introduced to the market. He further states “We believe by securing patent protection and/or orphan drug status, and establishing proof-of-concept in validated pre-clinical models may expedite the clinical development and regulatory pathway of our products and pave the way for partnering with pharmaceutical companies and licensed producers of medical cannabis.”
Products for liver diseases
Today, statistics by the World Liver Disease Treatment Market – Opportunities and Forecast, 2014 – 2022 show that there are over 30 million people in the US only, which suffer from about 100 described diseases of the liver. The costs of the various liver disease treatments are expected to reach about $19.5 billion by 2022 and the management behind Revive Therapeutics is hoping to lower this number and help many people get the treatment they deserve without the unwanted consequences that make their lives only harder.
As the company announced, they have developed and are now advancing their research program based solely on rare liver diseases. The Revive Therapeutics’ research program evaluates primarily cannabidiol or the CBD in the treatment of the autoimmune disease called hepatitis that attacks the liver and prevents it from regenerating and functioning normally.
Their new medical product is been overseen by Sanyal Biotechnology LLC (“SanyalBio”) which are now working on developing the CBD – based product specifically for Revive Therapeutics.
This research is expected to enable both companies to treat the autoimmune disease hepatitis, and other liver diseases like the non-alcoholic steatohepatitis or the NASH, and the non-alcoholic fatty liver disease or the NAFLD. Furthermore, the companies are being positive about fibrosis too, as a medical disease to be treated by their product.
Other orphan drug development
Pills and capsules via Pixabay.
As mentioned before, Revive Therapeutics has already received an orphan drug for further advancement by the FDA that is promising to the autoimmune disease of the liver hepatitis. In addition to this, the company has now submitted another application to the FDA for a second orphan drug that will be again CBD – based and will treat hepatic ischemia and reperfusion injury or IRI during liver transplantations.
With this, Revive Therapeutics has in their mission to build a portfolio of FDA orphan drugs based on cannabinoids that complement their cannabis-based pharmaceuticals. This, in turn, will support the potential of cannabis-derived medications to be used in the long term as an effective treatment against various diseases, including the rare ones as mentioned above.
Rare diseases in the world
The main reason why the Revive Therapeutics is predominantly focused on developing effective cannabis-based pharmaceuticals for rare diseases is that in today’s world there are 7000 different types of them recorded. What is even more staggering is the fact that approximately 30 million people suffer from any of the forms of these rare diseases which makes it a top priority for effective medication to be found. Because according to the EveryLife Foundation, 95% of the people suffering from rare diseases do not have an FDA approved drug treatment. This makes their lives even harder, which is why the Revive Therapeutics seeks to develop a potent cannabis-based medicine that will heal these illnesses without the unwanted side – effects.
Will this boost the production and advancement of cannabis-based medications for rare diseases? It remains to be seen, but with the legalization of marijuana all across the globe, and its research advancing, the future sure looks promising.
